Search
tropifexor
Indications:
- investigational treatment of primary biliary cholangitis [1]
Dosage:
- 20, 60 or 90 ug QD
Mechanism of action:
- farnesoid X receptor agonist [1]
Related
obeticholic acid; 6-ethylchenodeoxycholic acid; 6-ECDCA (Ocaliva)
General
gastrointestinal agent
References
- Walker M
Novel Non-Bile FXR Agonist Promising in PBC Patients
Phase II trial interim analysis found dose-dependent
response, good safety profile.
MedPage Today. April 15, 2018
https://www.medpagetoday.com/meetingcoverage/easl/72355
- Schramm C, et al
Early assessment of safety and efficacy of tropifexor, a
potent non bile-acid FXR agonist, in patients with primary
biliary cholangitis
European Association for the Study of the Liver (EASL) 2018.
Abstract LBO-007.